Takahashi, Hiroshi http://orcid.org/0000-0002-6563-7729
Suganuma, Yuka
Ohno, Takayuki
Nishimura, Rimei
Article History
Received: 13 December 2021
Accepted: 3 March 2022
First Online: 16 March 2022
Change Date: 12 December 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s13340-023-00685-3
Declarations
:
: Rimei Nishimura has participated in speakers’ bureaus/advisory panels for Astellas, Boehringer Ingelheim, Eli Lilly, Kissei, Medtronic, Novo Nordisk, Sanofi, Takeda, Novartis, and MSD and served as subsidies or donatins for Ono, Boehringer Ingelheim, Takeda, and Taisho. The other authors haven no conflict of interest to declare.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (Ethics Committee of Jikei University School of Medicine/November 12, 2018/No. 30–273 [9294]) and with the Helsinki Declaration of 1964 and later versions. This study used samples and medical information collected in the past in the course of normal medical care. Individual informed consent was not taken, but documents approved by the Ethics Committee were posted on the website to make the information available to the public, and the opportunity to refuse was provided.